Pfizer Doubles Dublin Biologicals Capacity
Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.
The pharma giant will build a new facility, creating another 400-500 jobs and ensuring it has capacity for licensed pipeline products in oncology, rare diseases, inflammation & immunology, and internal medicines.
Preliminary design work is currently under way, with construction expected to start in 2024 and completion scheduled for 2027.
Mike McDermott, chief global supply officer and executive vice president, said the investment significantly strengthens Pfizer’s operations in Ireland, helping to further expand Grange Castle’s “broad and robust capabilities.”
The announcement follows a €40 million investment at Grange Castle last year when the site was brought into Pfizer’s global Covid-19 manufacturing network. As well as Pfizer’s other manufacturing sites in Newbridge and Ringaskiddy, Ireland, Grange Castle manufacture medicines and vaccines in areas such as arthritis, inflammation, cancer, anti-infectives, hemophilia, pain and stroke.
Pfizer is also one of the investors, alongside other pharma giants AstraZeneca and GSK, in the Medicines Manufacturing Innovation Center that opened in Glasgow on Nov. 30.
Author: Elaine Burridge, Freelance Journalist
